Benzinga··Vandana SinghImmunityBio Surpasses Enrollment Target in Pivotal Cancer Study as Anktiva Sales Accelerate
ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.
IBRXFDA approvalbiotech